Program
JNJ-78934804
A development code.
Its studies are mostly in Colitis, Ulcerative · Crohn Disease, led by Johnson & Johnson.
Furthest: phase 3, since May 5, 20264 company-led studies, 4 open or runningNext primary completion: Jun 12, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 44 open or running | phase 3since May 5, 2026 | Feb 15, 2022 | Jun 12, 2028phase 3 · NCT07577843 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 15, 2022First studies: 2 phase 2 studiesFirst studyNCT05242484, NCT05242471
- May 5, 20262 phase 3 studiesPhase 3 reachedNCT07577856, NCT07577843
Ahead
- Jun 12, 2028Primary completion: phase 3 study in Crohn DiseaseNCT07577843
- Aug 11, 2028Primary completion: phase 3 study in Colitis, UlcerativeNCT07577856
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07577856Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Recruiting | Aug 11, 2028 | 644 |
| NCT07577843Crohn Disease · United States, Argentina, Australia and more | 3 | Recruiting | Jun 12, 2028 | 460 |
| NCT05242484Colitis, Ulcerative · United States, Argentina, Australia and more | 2 | Active, not recruiting | May 15, 2025 | 577 |
| NCT05242471Crohn Disease · United States, Australia, Austria and more | 2 | Active, not recruiting | May 23, 2025 | 703 |
How it is read
Names in the registry
- “JNJ-78934804”, 4 entries
Codes read as this program: JNJ78934804.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 2 studies
- Crohn Disease, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.